Chemotherapy and targeted treatment in metastatic colorectal cancer
MUDr. Jiří Tomášek, Ph.D.
Masarykův onkologický ústav, Brno
Approximately 40 % of patients with colorectal cancer will develop metastatic disease. Survival of patients with metastatic colorectal cancer has improved with the introduction of targeted therapies. Survival has also improved with utilization of molecular parameters (oncogens RAS, BRAF) and other factors such as sidedness of the primary tumor. The basics of intensive chemotherapy are regimens based on oxaliplatin and irinotecan. Targeted treatment increases the effectiveness of chemotherapy. A multidisciplinary approach to treatment is needed. In brief, we describe the basic strategy of systemic treatment in metastatic colorectal cancer
colorectal cancer, chemotherapy, targeted therapy
The full article is only available to subscribers
Become a regular subscriber to our Oncological Review...